January 2021 Simoa® Publications:
Infectious Disease, COVID-19 with Neurological Manifestations, Oncology, and Inflammation
Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy
Anderson AM, et al.
Journal of Neuroimmunology. 2021:577493.
HIV
Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue
Upasani V, et al.
Frontiers in Immunology. 2020;11:605087.
Dengue
Serum neurofilament light chain levels in the intensive care unit: comparison between severely ill patients with and without COVID-19
Sutter R, et al.
Ann Neurol. 2021.
COVID-19 with Neurological Manifestations
Biomarkers for CNS injury in CSF are elevated in COVID-19 and associated with neurological symptoms and disease severity
Virhammar J, et al.
European Journal of Neurology. 2021.
COVID-19 with Neurological Manifestations
A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
Choueiri TK, et al.
Invest New Drugs (2021).
Oncology
Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type
Li JW, et al.
Am J Cancer Res. 2021;10:4498-4512.
Oncology
Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MEK1) in Ileal Enterocytes Leads to Dysplasia and a Predisposition to Cancer
Shneider BL, et al.
Am J Physiol Gastrointest Liver Physiol. 2021
Oncology
Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies
Lodi L, et al.
J Clin Immunol. 2021.
Inflammation
January 2021 Simoa® Publications in Other Therapeutic Areas
